[go: up one dir, main page]

FI94340C - Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi - Google Patents

Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi

Info

Publication number
FI94340C
FI94340C FI872379A FI872379A FI94340C FI 94340 C FI94340 C FI 94340C FI 872379 A FI872379 A FI 872379A FI 872379 A FI872379 A FI 872379A FI 94340 C FI94340 C FI 94340C
Authority
FI
Finland
Prior art keywords
pyrazoles
diaryl
substituted
preparation
lower alkyl
Prior art date
Application number
FI872379A
Other languages
English (en)
Swedish (sv)
Other versions
FI94340B (fi
FI872379A0 (fi
FI872379A7 (fi
Inventor
Michael Paul Wachter
Michael Paul Ferro
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of FI872379A0 publication Critical patent/FI872379A0/fi
Publication of FI872379A7 publication Critical patent/FI872379A7/fi
Publication of FI94340B publication Critical patent/FI94340B/fi
Application granted granted Critical
Publication of FI94340C publication Critical patent/FI94340C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI872379A 1986-05-29 1987-05-28 Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi FI94340C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86799686A 1986-05-29 1986-05-29
US86799686 1986-05-29
US4266187 1987-04-29
US07/042,661 US4826868A (en) 1986-05-29 1987-04-29 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use

Publications (4)

Publication Number Publication Date
FI872379A0 FI872379A0 (fi) 1987-05-28
FI872379A7 FI872379A7 (fi) 1987-11-30
FI94340B FI94340B (fi) 1995-05-15
FI94340C true FI94340C (fi) 1995-08-25

Family

ID=26719497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI872379A FI94340C (fi) 1986-05-29 1987-05-28 Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi

Country Status (21)

Country Link
US (1) US4826868A (fi)
EP (1) EP0248594B1 (fi)
JP (1) JP2512751B2 (fi)
KR (1) KR960007163B1 (fi)
CN (1) CN1028227C (fi)
AU (1) AU596844B2 (fi)
CA (1) CA1337122C (fi)
DE (2) DE10199049I2 (fi)
DK (1) DK170202B1 (fi)
ES (1) ES2059377T3 (fi)
FI (1) FI94340C (fi)
HK (1) HK14094A (fi)
HU (1) HU221300B1 (fi)
IE (1) IE63856B1 (fi)
IL (1) IL82671A0 (fi)
LU (1) LU90829I2 (fi)
NL (1) NL300057I2 (fi)
NO (2) NO172236C (fi)
NZ (1) NZ220353A (fi)
PH (1) PH25126A (fi)
PT (1) PT84964B (fi)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898952A (en) * 1987-05-29 1990-02-06 Ortho Pharmaceutical Corporation Regioselective synthesis of a 1,5-disubstituted pyrazole
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
EP0293221A3 (en) * 1987-05-29 1990-07-04 Ortho Pharmaceutical Corporation Regioselective synthesis of 1,5-disubstituted pyrazoles
CA1334975C (en) * 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2052950A1 (en) * 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5117054A (en) * 1991-09-26 1992-05-26 Ortho Pharmaceutical Corporation N-hydroxy, N-methyl propanamides
US5260458A (en) * 1991-09-26 1993-11-09 Ortho Pharmaceutical Corporation 2-oxo tetrahydrofuran compounds
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5387602A (en) * 1993-08-30 1995-02-07 Ortho Pharmaceutical Corporation 1.5-diphenyl-3-(N-hydroxycarbamoyloxyalkyl)pyrazoles
IL111613A0 (en) * 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
ATE233245T1 (de) * 1993-11-30 2003-03-15 Searle & Co Substituierte pyrazolyl-benzolsulfonamide und ihre verwendung als cyclooxygenaseii inhibitoren
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
JPH10509140A (ja) * 1994-11-08 1998-09-08 エーザイ株式会社 ピラゾール誘導体
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
DE69531555T2 (de) * 1994-12-13 2004-06-17 Euroceltique S.A. Dreifachsubstituierte thioxanthine
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2224517A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
PT1144382E (pt) * 1999-08-03 2005-02-28 Ortho Mcneil Pharm Inc Processo para a preparacao de 1,5-diaril-3-(substituido)pirazoles
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004016592A1 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004016741A2 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
AU2003275637A1 (en) * 2002-10-24 2004-05-13 Wakamoto Pharmaceutical Co., Ltd. Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase
NZ540515A (en) * 2002-12-02 2008-01-31 Astellas Pharma Inc Pyrazole derivatives useful as COX-I inhibitors
EP1613614A2 (en) * 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20050020565A1 (en) * 2003-07-02 2005-01-27 Jones Todd K. CCK-1 receptor modulators
KR20060030506A (ko) * 2003-07-02 2006-04-10 얀센 파마슈티카 엔.브이. Ｃｃｋ-1 수용체 조절제
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
US20070060629A1 (en) * 2003-10-17 2007-03-15 Yasuhiro Imanishi Large conductance calcium-activated k channel opener
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
MXPA06014551A (es) * 2004-06-30 2007-06-05 Johnson & Johnson Esteres y acidos alfa,beta no saturados mediante deshidratacion estereoselectiva.
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
EP2124944B1 (en) * 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
WO2011161645A1 (en) * 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
JP2013533258A (ja) * 2010-06-28 2013-08-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 細胞増殖を阻害するための化合物
US8492424B2 (en) * 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2861562B1 (en) * 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755924A (fr) * 1969-09-12 1971-02-15 Byk Gulden Lomberg Chem Fab Derives d'acide pyrazole-4-acetique, leur procede de preparation et medicaments en contenant
GB1373212A (en) * 1970-12-07 1974-11-06 Wyeth John & Brother Ltd Pyrazole compounds
US3974176A (en) * 1973-08-16 1976-08-10 Byk-Gulden Lomberg Chemische Fabrik Gmbh Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them
DE2633992A1 (de) * 1975-08-08 1978-02-09 Schering Ag Neue pyrazol-derivate, ihre herstellung und verwendung
DE2906252A1 (de) * 1979-02-19 1980-08-28 Merck Patent Gmbh Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
DE3205187A1 (de) * 1982-02-13 1983-08-25 Hoechst Ag, 6230 Frankfurt Substituierte phenylpyrazolderivate, verfahren zu ihrer herstellung, arzneimittel auf basis dieser verbindungen, sowie deren verwendung

Also Published As

Publication number Publication date
EP0248594A3 (en) 1988-11-17
CA1337122C (en) 1995-09-26
CN87103953A (zh) 1987-12-09
KR960007163B1 (ko) 1996-05-29
HU221300B1 (en) 2002-09-28
DK170202B1 (da) 1995-06-12
CN1028227C (zh) 1995-04-19
FI94340B (fi) 1995-05-15
KR870011100A (ko) 1987-12-21
DK273587A (da) 1987-11-30
DE3788244D1 (de) 1994-01-05
HUT68247A (en) 1995-06-28
NL300057I1 (nl) 2001-12-01
LU90829I2 (fr) 2001-11-12
PT84964A (en) 1987-06-01
ES2059377T3 (es) 1994-11-16
IL82671A0 (en) 1987-11-30
HK14094A (en) 1994-03-04
NO872228D0 (no) 1987-05-27
EP0248594A2 (en) 1987-12-09
JPS6322080A (ja) 1988-01-29
PT84964B (pt) 1990-02-08
DE10199049I2 (de) 2003-01-09
EP0248594B1 (en) 1993-11-24
IE63856B1 (en) 1995-06-14
AU596844B2 (en) 1990-05-17
US4826868A (en) 1989-05-02
NO172236B (no) 1993-03-15
IE871403L (en) 1987-11-29
PH25126A (en) 1991-02-19
NO872228L (no) 1987-11-30
FI872379A0 (fi) 1987-05-28
JP2512751B2 (ja) 1996-07-03
NL300057I2 (nl) 2002-01-02
FI872379A7 (fi) 1987-11-30
DK273587D0 (da) 1987-05-27
DE3788244T2 (de) 1994-04-14
NZ220353A (en) 1989-05-29
NO172236C (no) 1993-06-23
AU7360887A (en) 1987-12-10
NO2001016I1 (no) 2001-10-01
DE10199049I1 (de) 2002-01-10

Similar Documents

Publication Publication Date Title
FI94340C (fi) Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi
FI890282A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI875681L (fi) Menetelmä farmaseuttisesti aktiivisten 4-(2,6,6-trimetyyli-sykloheks-1-enyl)-but-3-en-1-ynyylisubstituoitujen yhdisteiden valmistamiseksi
FI873205A0 (fi) Menetelmä terapeuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
NO831679L (no) Fremgangsmaate for fremstilling av farmakologisk aktive 1,3-dioksan-5-yl-alkensyrer
FI871087A0 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
FI872255A7 (fi) Menetelmä uusien, farmaseuttisesti aktiivisten 1-(hydroksistyryyli)-5H-2,3-bentsodiatsepiinijohdannaisten valmistamiseksi
FI903077A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia R(-)-3-kinuklidinolijohdannaisia
FI884660A0 (fi) Menetelmä terapeuttisesti aktiivisten 2,2-dimetyylikromeenijohdannaisten valmistamiseksi
FI100799B (fi) Menetelmä terapeuttisesti aktiivisten tetraliinijohdannaisten valmista miseksi
FI896075A7 (fi) Menetelmä 4,5,6,7-tetrahydrobentsimidatsolijohdosten valmistamiseksi
FI882165A7 (fi) Menetelmä 4-amino-androsteenidioni-johdannaisten valmistamiseksi.
FI901883A0 (fi) Menetelmä terapeuttisesti vaikuttavien 2-substituoitujen N,N'-ditrimetoksibentsoyylipiperatsiinien valmistamiseksi
FI900145A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
FI901606A0 (fi) Tieno-triatsolo-diatsepiinien sulfonyylijohdosten valmistusmenetelmä
FI881610A7 (fi) Menetelmä sytostaattisesti aktiivisten -rodomysinonijohdannaisten valmistamiseksi
FI871535A7 (fi) Menetelmä terapeuttisesti aktiivisten tiasykloalkeno/3,2-b/pyridiinien valmistamiseksi
FI893121A0 (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
FI894392A0 (fi) Menetelmä rytmihäiriöiden vastaisten imidatsolien valmistamiseksi
FI884461A7 (fi) Menetelmä trans-1,1,2-trifenyylibut-1-eenijohdannaisten valmistamiseksi
FI874413A7 (fi) Menetelmä aralkyyli-4H-1,2,4 -triatsolijohdannaisten valmistamiseksi.
PT86623A (pt) Process for the preparation of derivatives of 3-aryl-5-alkylthio-4h-1,2,4-triazoles
FI891111A0 (fi) Menetelmä 1,4-dihydropyridiinijohdannaisten valmistamiseksi
FI93216C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1,3-dioksaanialkeenihappojohdannaisten valmistamiseksi
FI842976A7 (fi) Menetelmä farmaseuttisesti aktiivisten aminopyrimidinonijohdannaisten valmistamiseksi.

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: ORTHO PHARMACEUTICAL CORPORATION

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L187

Extension date: 20120527

MA Patent expired